Can HPA-axis disruption, zinc insufficiency, DIO variants, gut-liver stress, and inflammation converge on T4-to-T3 conversion?

Peripheral thyroid hormone activation—the conversion of thyroxine (T4) to active triiodothyronine (T3)—is a dynamic metabolic process highly sensitive to systemic, environmental, and genetic stressors.

Mechanistic convergence on deiodinases

• Inflammatory and HPA-axis suppression: Elevated cortisol (from HPA-axis disruption) and pro-inflammatory cytokines (IL-6, TNF-α, IL-1β) transcriptionally repress DIO1 and DIO2 expression. This suppression is heavily driven by the NF-κB pathway, which directly represses DIO1 transcription and blocks deiodinase upregulation. Concurrently, these signals upregulate type 3 deiodinase (D3), shunting T4 into inactive reverse T3 (rT3).
• Gut-liver assimilation stress: Hepatic stress and circulating bacterial lipopolysaccharides (LPS) directly suppress hepatic type 1 deiodinase (D1) activity. Furthermore, gut dysbiosis reduces microbial sulfatase and β-glucuronidase activity, compromising the enterohepatic recycling of thyroid hormones and causing excessive fecal loss of thyroid precursors.
• Zinc cofactor deficiency: Although deiodinases are selenoproteins, zinc is an essential structural and regulatory cofactor for both D1 and D2. Zinc insufficiency destabilizes enzyme folding and increases local oxidative stress, damaging the sensitive catalytic sites required for active T3 production.

Genetic and clinical implications

• Genetic variant load: Inherited polymorphisms, such as the DIO2 Thr92Ala (rs225014) variant and DIO1 SNP rs2235544, directly reduce deiodinase catalytic efficiency. This genetic burden manifests as lower free T3 (FT3) levels and reduced FT3/FT4 ratios, especially in patients receiving levothyroxine monotherapy.
• Clinical presentation: Together, these pathways drive a non-thyroidal illness phenotype (low FT3, high rT3). Clinical trials demonstrate that addressing specific underlying blocks—such as supplementing 30 mg/day of zinc—can significantly improve the FT3/FT4 ratio in individuals with baseline deficiencies or metabolic stress.

Bottom line

• Physiological stressors, nutritional deficiencies, genetic DIO polymorphisms, and gut-derived inflammatory signaling converge to suppress activating deiodinases (D1/D2) and induce inactivating pathways (D3), resulting in functional tissue-level hypothyroidism independent of primary thyroid gland failure.